Why Most Published Research Findings Are False
This paper argues, using a Bayesian probability model, that the majority of statistically significant findings in published research are likely wrong — because most hypotheses tested are false to begin with, studies are underpowered, and bias is pervasive. The mathematical framework is sound and the qualitative insight is important, but the headline claim that this has been "proven" overreaches what the model actually establishes, since its conclusions depend entirely on assumed parameter values the paper never validates empirically.
What this paper claims
The paper argues that when you account for how rarely tested hypotheses are true, how underpowered most studies are, and how much bias distorts results, the majority of statistically significant findings in published research are probably wrong. It presents this not as speculation but as something that "can be proven."
What evidence it offers
This is a theoretical argument built on Bayes' theorem. There is no new data. The paper derives a formula for how often a statistically significant finding reflects a real relationship, then plugs in assumed values for different research types to show that, under those assumptions, most findings would be false. The strength of this evidence depends entirely on whether the assumptions are correct — and that is where the paper's certainty outpaces its support.
What's good
The paper formalizes something researchers sensed but hadn't rigorously articulated: the reliability of a finding depends on how likely the hypothesis was to be true before anyone tested it. A genome-wide scan testing 100,000 genetic variants has fundamentally different reliability properties than a confirmatory trial testing one well-supported intervention, even if both produce identical p-values. This insight, expressed through a clean mathematical framework, catalyzed real reforms — pre-registration, larger replication studies, greater attention to statistical power — that have measurably improved research practices.
What's wrong with it
The model proves a conditional: given certain assumptions about how often hypotheses are true, how powerful studies are, and how much bias exists, most findings would be false. The paper claims an unconditional: most findings are false. Bridging that gap requires knowing the actual distribution of these parameters across real research — and the paper substitutes the author's guesses for empirical evidence, then presents the conclusions as proven.
The simulation table — the paper's primary bridge between theory and reality — depends entirely on assumed values for pre-study odds and bias that are plausible but unvalidated. The model is sensitive to these inputs: modest adjustments could shift many scenarios from "probably false" to "probably true." The one-sided citation practice reinforces this by presenting only evidence that makes the pessimistic parameter values seem inevitable.
What would change our mind
- Large-scale replication studies sampling randomly across published findings would directly test the headline claim. Results from projects like the Reproducibility Project in psychology and economics have partially supported the paper's direction, though replication rates vary enormously by field and study type. More such evidence, especially from fields the paper singles out (genetic epidemiology, nutritional epidemiology), would move confidence up.
- Empirical estimates of pre-study odds and bias for specific research fields would either validate or undermine the simulation table's assumed parameter values. If measured values turned out substantially more favorable than assumed, the headline claim would not hold. This would move confidence down.
- Evidence that intelligent hypothesis selection substantially raises effective pre-study odds — showing that hypotheses researchers actually test and publish are drawn from a much more favorable pool than naive counts suggest — would weaken the paper's most alarming scenarios. This would move confidence down.
- Systematic data on how false-positive rates change as findings accumulate replications and meta-analyses would test whether the paper's static, single-study framework captures the reliability of established conclusions or only of initial claims. This would move confidence down if cumulative evidence is substantially more reliable than isolated findings.
Scoring Explanation
The mathematical core is valid. If you accept the inputs — how often hypotheses are true, how powerful the studies are, how much bias operates — the formula correctly tells you how often positive findings will be wrong. The six corollaries all follow logically from the model.
The problem is the bridge between the model and the headline. "Most published research findings are false" is a claim about the actual world. To get from the model to the world, you need to know what fraction of research operates in the parameter ranges where findings are mostly false — and the paper provides no empirical evidence for this. The simulation table shows various scenarios, but the values plugged in are the author's own estimates. Modestly different but equally plausible values could reach substantially less alarming conclusions.
The bias parameter is particularly problematic. The paper assigns bias values of 10% to 80% for different research types, but these are stipulated, not measured. Since the model's outputs are highly sensitive to this parameter, the numerical conclusions inherit whatever accuracy or inaccuracy these guesses carry.
The paper also doesn't address its strongest counterargument: researchers don't test hypotheses at random. A geneticist studying a candidate gene identified through decades of functional biology draws from a very different hypothesis pool than a genome-wide scan testing 100,000 variants. If most published findings come from research where prior evidence has already filtered out implausible hypotheses, the effective odds could be substantially better than assumed.
The formula is precise: given its inputs, it outputs an exact probability. But the two inputs doing the most work — pre-study odds and bias — are defined in ways that make them practically unmeasurable.
Pre-study odds (the ratio of true to false hypotheses in a field) requires knowing how many true relationships exist before doing the research — which is what the research is supposed to discover. The paper treats this as a definite quantity while acknowledging it must be guessed. The bias parameter collapses wildly different phenomena — dropping outliers, switching outcomes after seeing results, running twenty subgroup analyses — into a single number, with no empirical basis for the values chosen.
The framework also treats "true relationship" as binary, but most biological relationships exist on a continuum of effect sizes. Whether a genetic variant that raises disease risk by a factor of 1.001 counts as a "true relationship" is a judgment call the model treats as settled.
These definitional issues mean the framework does useful qualitative work — it correctly identifies the structural factors that make findings unreliable — but its apparent quantitative precision (85% for a good trial, 0.1% for discovery-oriented research) masks that these numbers are outputs of guesses.
The core insight is genuinely important: the reliability of a finding depends not just on the study itself but on how likely the hypothesis was to be true before anyone tested it. This is a direct application of Bayes' theorem and is mathematically unimpeachable.
The problem is that the paper presents conditional predictions as established facts. "It can be proven that most claimed research findings are false" is doing rhetorical work the math does not support. What the model proves is that if pre-study odds, power, and bias take certain values, then most findings will be false. Whether those values obtain is an empirical question the paper never answers.
The simulation table illustrates this gap. It shows what the model predicts under chosen parameter values — not measurements of actual false-positive rates. But the paper presents them as descriptions of reality rather than sensitivity analyses.
The paper also doesn't engage with science's self-correcting mechanisms — replication, meta-analysis, theoretical integration. The model evaluates isolated findings at publication, ignoring the cumulative process by which false findings are identified and corrected.
The mathematical framework is fully explicit and independently verifiable. The premises are clearly stated, and each step from assumptions to conclusions can be traced. The paper calls its simulation examples "illustrative" and acknowledges that its parameter estimates are "considerably subjective."
What prevents a higher rating is the gap between this local honesty and the global framing. The title and abstract claim proof where the model offers only conditional prediction. A careful reader can identify where the formal apparatus ends and editorial judgment begins, but only by reading past the assertive framing to hedged language buried in the body text.
Individual citations are accurate — when the paper says a study showed selective outcome reporting (Chan et al. 2004), it did. The problem is one-sidedness. The literature review cites only work supporting the conclusion that research is unreliable. No cited source challenges the model's assumptions, presents evidence of successful replication, or argues that the parameter estimates might be too pessimistic.
Roughly a quarter of the references are to the author's own work or that of close collaborators. Several occupy positions where independent corroboration would have strengthened the argument.
This is an unfunded theoretical essay by an academic epidemiologist with no disclosed conflicts of interest. The thesis runs directly against the institutional interests of the research establishment the author belongs to. No identifiable party benefits structurally from this claim.
Key Claims
Most published research findings are false
The paper builds a valid mathematical model showing that false findings can outnumber true ones when researchers test unlikely hypotheses with underpowered studies and flexible methods. But the headline conclusion requires knowing three things the paper never measures: how often researchers test true hypotheses, how much bias operates in practice, and what power levels are typical. The paper fills in these numbers with the author's own estimates — for instance, assuming a well-run clinical trial has 10% bias and discovery-oriented research has 80%. Swap in modestly different but equally plausible values and the conclusion changes substantially. The model proves that most findings *can* be false under specific conditions; it does not establish that they *are*.
Underpowered studies, flexible methods, and low prior plausibility make research findings unreliable
The model's core insight is a straightforward application of probability: if you test a hypothesis that was unlikely to be true in the first place, using a study too small to detect real effects, and allow yourself flexibility in how you analyze the data, the chance that a positive result reflects reality drops sharply. For example, the model shows that an adequately powered clinical trial testing a plausible hypothesis has roughly an 85% chance of being correct, while a discovery-oriented study screening thousands of genes has less than a 1% chance — a difference driven entirely by how many false leads are in the pool. This conditional reasoning is mathematically sound and does not depend on the contested assumptions behind the headline claim.
In some research fields, the reported effects are not real — they are just measuring the field's collective biases
The paper observes that if a field has no real effects to find, then every reported result is an artifact of selective reporting, flexible analysis, or other distortions — and the size of reported effects simply reflects how much bias the field sustains. As a thought experiment this follows logically, but the paper provides no way to determine whether any actual field fits this description. Its example — nutritional epidemiology claiming dozens of nutrients affect cancer risk — is offered as an illustration, not demonstrated with evidence. The interesting question the paper cannot answer is how to tell a field with no real effects from one with real but small and noisy effects.
References (37)
- Ioannidis, Haidich, Lau (2001). Any casualties in the clash of randomised and observational evidence?. BMJ
- Lawlor et al. (2004). Those confounded vitamins: What can we learn from the differences between observational versus randomised trial evidence?. Lancet
- Vandenbroucke (2004). When are observational studies as credible as randomised trials?. Lancet
- Michiels, Koscielny, Hill (2005). Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet
- Ioannidis et al. (2001). Replication validity of genetic association studies. Nature Genetics
- Colhoun, McKeigue, Davey Smith (2003). Problems of reporting genetic associations with complex outcomes. Lancet
- Ioannidis (2003). Genetic associations: False or true?. Trends in Molecular Medicine
- Ioannidis (2005). Microarrays and molecular research: Noise discovery?. Lancet
- Sterne, Davey Smith (2001). Sifting the evidence—What's wrong with significance tests. BMJ
- Wacholder et al. (2004). Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. Journal of the National Cancer Institute
- Risch (2000). Searching for genetic determinants in the new millennium. Nature
- Kelsey et al. (1996). Methods in observational epidemiology, 2nd ed.. Oxford University Press
- Topol (2004). Failing the public health—Rofecoxib, Merck, and the FDA. New England Journal of Medicine
- Yusuf, Collins, Peto (1984). Why do we need some large, simple randomized trials?. Statistics in Medicine
- Altman, Royston (2000). What do we mean by validating a prognostic model?. Statistics in Medicine
- Taubes (1995). Epidemiology faces its limits. Science
- Golub et al. (1999). Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science
- Moher, Schulz, Altman (2001). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet
- Ioannidis et al. (2004). Better reporting of harms in randomized trials: An extension of the CONSORT statement. Annals of Internal Medicine
- International Conference on Harmonisation E9 Expert Working Group (1999). ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Statistics in Medicine
- Moher et al. (1999). Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Lancet
- Stroup et al. (2000). Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA
- Marshall et al. (2000). Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry
- Altman, Goodman (1994). Transfer of technology from statistical journals to the biomedical literature. Past trends and future predictions. JAMA
- Chan et al. (2004). Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA
- Krimsky et al. (1998). Scientific journals and their authors' financial interests: A pilot study. Psychotherapy and Psychosomatics
- Papanikolaou et al. (2001). Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions. BMC Medical Research Methodology
- Antman et al. (1992). A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA
- Ioannidis, Trikalinos (2005). Early extreme contradictory estimates may appear in published research: The Proteus phenomenon in molecular genetics research and randomized trials. Journal of Clinical Epidemiology
- Ntzani, Ioannidis (2003). Predictive ability of DNA microarrays for cancer outcomes and correlates: An empirical assessment. Lancet
- Ransohoff (2004). Rules of evidence for cancer molecular-marker discovery and validation. Nature Reviews Cancer
- Lindley (1957). A statistical paradox. Biometrika
- Bartlett (1957). A comment on D.V. Lindley's statistical paradox. Biometrika
- Senn (2001). Two cheers for P-values. Journal of Epidemiology and Biostatistics
- De Angelis et al. (2004). Clinical trial registration: A statement from the International Committee of Medical Journal Editors. New England Journal of Medicine
- Ioannidis (2005). Contradicted and initially stronger effects in highly cited clinical research. JAMA
- Hsueh, Chen, Kodell (2003). Comparison of methods for estimating the number of true null hypotheses in multiplicity testing. Journal of Biopharmaceutical Statistics
Cited by — in tracked papers (13)
- P. Boffetta et al. (2008). False-Positive Results in Cancer Epidemiology: A Plea for Epistemological Modesty. JNCI Journal of the National Cancer Institute
- Neal S Young, John P. A Ioannidis, Omar Al-Ubaydli (2008). Why Current Publication Practices May Distort Science. PLoS Medicine
- Daniele Fanelli (2010). “Positive” Results Increase Down the Hierarchy of the Sciences. PLoS ONE
- Joseph P. Simmons, Leif D. Nelson, Uri Simonsohn (2011). False-Positive Psychology. Psychological Science
- John P. A. Ioannidis, Muin J. Khoury (2011). Improving Validation Practices in “Omics” Research. Science
- Joshua K. Hartshorne, Adena Schachner (2011). Tracking Replicability as a Method of Post-Publication Open Evaluation. Frontiers in Computational Neuroscience
- Story C. Landis et al. (2012). A call for transparent reporting to optimize the predictive value of preclinical research. Nature
- Joseph Loscalzo (2012). Irreproducible Experimental Results. Circulation
- Timothy M Errington et al. (2014). An open investigation of the reproducibility of cancer biology research. eLife
- E. Miguel et al. (2014). Promoting Transparency in Social Science Research. Science
- Open Science Collaboration (2015). Estimating the reproducibility of psychological science. Science
- Colin F. Camerer et al. (2016). Evaluating replicability of laboratory experiments in economics. Science
- Timothy M Errington et al. (2021). Investigating the replicability of preclinical cancer biology. eLife